|
Family Health History
|
Health Survey
|
CDC, HRSA, OS, OSG
|
NCI, NHGRI, NLM
|
My Family Health Portrait is the Web-based tool from NHGRI and the U.S. Surgeon General’s Family History Initiative that helps individuals track their family health history. Using any computer, an Internet connection and an up-to-date Web browser, individuals can provide health information to build a drawing of their family tree and a chart of their family health history. Both the chart and the drawing can be printed and shared with family members and an individual’s doctor.
|
|
Fatherhood Outreach: Implications of Men''s Health and Community Engagement in Pregnancy Outcomes
|
Meeting/ Workshop
|
ACF
|
NICHD
|
In 2013, NICHD, in collaboration with the Administration for Children and Families, the Maternal & Child Health Bureau of the Health Resources and Services Administration, and the NIH Office of Behavioral and Social Sciences Research held a workshop entitled, “Paternal Involvement in Pregnancy Outcomes to identify research gaps in topics related to fathers’ role in pregnancy outcomes”. This is a follow-up meeting that will focused on community engagement with fathers to support healthy pregnancy outcomes. The objectives of this 2-day workshop were to: •Increase awareness of the role of men’s health in pregnancy outcomes •Identify potential collaborations between researchers and community organizations and innovative strategies for engaging fathers in research to support healthy pregnancy outcomes. This workshop included presentations from both academic researchers and community organization representatives with interests in engaging fathers in research to promote healthy pregnancy outcomes.
|
|
FDA Blood Product Advisory Committee
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA
|
NHLBI, CC
|
The Food and Drug Administration (FDA) Blood Products Advisory Committee advises the FDA regarding issues of blood safety and efficacy. The committee reviews and evaluates available data concerning the safety, effectiveness, and appropriate use of blood, products derived from blood and serum or biotechnology which are intended for use in the diagnosis, prevention, or treatment of human diseases.
|
|
FDA Cancer Imaging Program (CIP) Bi-annual Meeting
|
Meeting/ Workshop
|
FDA
|
NCI
|
This collaboration is a bi-annual meeting to enhance communication between the Cancer Imaging Program (CIP) and the Division of Medical Imaging Products of CDER in the FDA. This allows for a two-way exchange of information and discussion of issues that are important for each side. Topics that have been discussed include CIP''s standardization efforts of medical imaging scanners in NCI Cancer Centers, presentation and discussion of specific new molecular imaging modalities, and discussion of recent FDA decisions regarding new medical imaging innovations.
|
|
FDA Drug Safety Oversight Board
|
Committee, Work group, Advisory group, or Task Force
|
AHRQ, CDC, CMS, FDA, HRSA, IHS
|
OD/OSP, NCI
|
The FDA Drug Safety Oversight Board (DSB), created in 2005 and mandated by law in the FDA Amendments Act of 2007, advises the FDA''s Center for Drug Evaluation and Research (CDER) Center Director on the handling and communicating of important and often emerging drug safety issues and regulatory science. The DSB is composed of representatives from two FDA Centers and eight other federal government agencies: the Agency for Healthcare Research and Quality (AHRQ), Centers for Disease Control and Prevention (CDC), Centers for Medicare and Medicaid Services (CMS), Department of Defense (DOD), Health Resources and Services Administration (HRSA), Indian Health Service (IHS), National Institutes of Health (NIH), and Department of Veterans Affairs (VA). An important role of the DSB is to help FDA assess the impact of their safety decisions on the healthcare systems of its Federal Partners. The Board, with its broad representation from federal healthcare organizations, can provide valuable input and allows FDA to hear other perspectives on drug safety issues.
|
|
FDA Medical Countermeasures Initiative (MCMi) Regulatory Science Steering Committee
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NIAID
|
This committee provides guidance to the Medical Countermeasures Initiative (MCMi) stakeholders.
|
|
FDA Memorandum of Understanding with NHLBI [Docket No. FDA–2008–N–0043]
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NHLBI
|
The group meets quarterly at alternate sites to discuss stem cell research, cell therapy research, and clinical trials related to these areas. Group members are invited to attend the Center for Biologics Evaluation and Research (CBER) or NHLBI working groups and workshops on these topics.
|
|
FDA Pediatric Advisory Committee (PAC) Neonatal Subcommittee
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NICHD
|
This committee addresses the need to expand current pediatric science to include the neonatal population. The committee addresses the challenges and identifies different programmatic strategies for advancing the knowledge necessary to develop neonatal regulatory science.
|
|
FDA Substance Registry System Public Interface
|
Resource Development
|
FDA
|
NLM
|
The National Library of Medicine (NLM) and the Food and Drug Administration (FDA) established a collaborative effort to provide an interface for public access to the FDA’s Substance Registration System (SRS). The FDA SRS utilizes an existing NLM database backend architecture to provide public search capability for FDA substances and medicinal products.
|
|
FDA-NCI Every Other Month Meeting
|
Meeting/ Workshop
|
FDA
|
NCI
|
An every other month meeting to enhance communication between the two agencies, thereby expediting the development of new anti-cancer agents. General topics discussed include patient safety, clinical efficacy, and regulatory pathways to licensure; as well as an understanding of the operations of the sister agencies.
|